Abstract
To estimate the cost of implementing a clinical program designed to support safer use of antipsychotics in children and adolescents (youth) age 3–17 years at the time of initiating an antipsychotic medication. We calculate the costs of implementing a psychiatric consultation and navigation program for youth prescribed antipsychotic medications across 4 health systems, which included an electronic health record (EHR) decision support tool, consultation with a child and adolescent psychiatrist, and up to 6 months of behavioral health care navigation, as well as telemental health for patients (n = 348). Cost data were collected for both start-up and ongoing intervention phases and are estimated over a 1-year period. Data sources included study records and time-in-motion reports, analyzed from a health system perspective. Costs included both labor and nonlabor costs (2019 US dollars). The average total start-up and ongoing costs per health system were $34,007 and $185,174, respectively. The average total cost per patient was $2,128. The highest average ongoing labor cost components were telemental health ($901 per patient), followed by child and adolescent psychiatrist consultation ($659), and the lowest cost component was primary care/behavioral health provider time to review/respond to the EHR decision support tool and case consultation ($24). For health systems considering programs to promote safer and targeted use of antipsychotics among youth, this study provides estimates of the full start-up and ongoing costs of an EHR decision support tool, psychiatric consultation service, and psychotherapeutic services for patients and families.
Trial registration: Clinicaltrials.gov, NCT03448575
Similar content being viewed by others
References
Akincigil, A., Mackie, T. I., Cook, S., Hilt, R. J., & Crystal, S. (2020). Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children. Health Services Research, 55(4), 596–603. https://doi.org/10.1111/1475-6773.13297
Barclay, R. P., Penfold, R. B., Sullivan, D., Boydston, L., Wignall, J., & Hilt, R. J. (2017). Decrease in statewide antipsychotic prescribing after implementation of child and adolescent psychiatry consultation services. Health Services Research, 52(2), 561–578. https://doi.org/10.1111/1475-6773.12539
Bobo, W. V., Cooper, W. O., Stein, C. M., Olfson, M., Graham, D., Daugherty, J., . . . Ray, W. A. (2012). Antipsychotics and the risk of type 2 diabetes in children and youth. Pharmacoepidemiology and Drug Safety, 21, 166–166. Retrieved from <Go to ISI>://WOS:000308131701341
Bowser, D. M., Henry, B. F., & McCollister, K. E. (2021). Cost analysis in implementation studies of evidence-based practices for mental health and substance use disorders: A systematic review. Implementation Science. https://doi.org/10.1186/s13012-021-01094-3
Bushnell, G. A., Crystal, S., & Olfson, M. (2021). Trends in antipsychotic medication use in young privately insured children. Journal of the American Academy of Child and Adolescent Psychiatry, 60(7), 877–886. https://doi.org/10.1016/j.jaac.2020.09.023
Constantine, R., Bengtson, M. A., Murphy, T., McPherson, M., Andel, R., Jones, M. E., & Donaldson-Guenther, C. (2012). Impact of the florida medicaid prior-authorization program on use of antipsychotics by children under age six. Psychiatric Services, 63(12), 1257–1260. https://doi.org/10.1176/appi.ps.201100346
Federal Contributions Act, 3121, (1958).
Crystal, S., Mackie, T., Fenton, M. C., Amin, S., Neese-Todd, S., Olfson, M., & Bilder, S. (2016). Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain. Health Aff (millwood), 35(6), 974–982. https://doi.org/10.1377/hlthaff.2016.0064
Daviss, W. B., Barnett, E., Neubacher, K., & Drake, R. E. (2016). Use of antipsychotic medications for nonpsychotic children: risks and implications for mental health services. Psychiatric Services, 67(3), 339–341. https://doi.org/10.1176/appi.ps.201500272
Edelsohn, G. A., Karpov, I., Parthasarathy, M., Hutchison, S. L., Castelnovo, K., Ghuman, J., & Schuster, J. M. (2017). Trends in antipsychotic prescribing in medicaid-eligible youth. Journal of the American Academy of Child and Adolescent Psychiatry, 56(1), 59–66. https://doi.org/10.1016/j.jaac.2016.10.005
Eisman, A. B., Kilbourne, A. M., Dopp, A. R., Saldana, L., & Eisenberg, D. (2020). Economic evaluation in implementation science: Making the business case for implementation strategies. Psychiatry Research. https://doi.org/10.1016/j.psychres.2019.06.008
Fischer, M. A., Vogeli, C., Stedman, M., Ferris, T., Brookhart, M. A., & Weissman, J. S. (2008). Effect of electronic prescribing with formulary decision support on medication use and cost. Archives of Internal Medicine, 168(22), 2433–2439. https://doi.org/10.1001/archinte.168.22.2433
Galling, B., Roldan, A., Nielsen, R. E., Nielsen, J., Gerhard, T., Carbon, M., & Correll, C. U. (2016). Type 2 diabetes mellitus in youth exposed to antipsychotics a systematic review and meta-analysis. JAMA Psychiatry, 73(3), 247–259. https://doi.org/10.1001/jamapsychiatry.2015.2923
Ghandour, R. M., Sherman, L. J., Vladutiu, C. J., Ali, M. M., Lynch, S. E., Bitsko, R. H., & Blumberg, S. J. (2019). Prevalence and Treatment of Depression, Anxiety, and Conduct Problems in US Children. Journal of Pediatrics. https://doi.org/10.1016/j.jpeds.2018.09.021
Gold, H. T., McDermott, C., Hoomans, T., & Wagner, T. H. (2022). Cost data in implementation science: Categories and approaches to costing. Implementation Science, 17(1), 11. https://doi.org/10.1186/s13012-021-01172-6
Hartzler, A. L., Ralston, J. D., Hannan, T. A., Kelleher, K. J., & Penfold, R. B. (2019). Designing Safer Use of Antipsychotics Among Youths: A Human-Centered Approach to an Algorithm-Based Solution. Psychiatric Services, 70(10), 944–947. https://doi.org/10.1176/appi.ps.201800390
Hoge, M. A., Stuart, G. W., Morris, J., Flaherty, M. T., Paris, M., Jr., & Goplerud, E. (2013). Mental health and addiction workforce development: Federal leadership is needed to address the growing crisis. Health Aff (millwood), 32(11), 2005–2012. https://doi.org/10.1377/hlthaff.2013.0541
Lewkowicz, D., Wohlbrandt, A., & Boettinger, E. (2020). Economic impact of clinical decision support interventions based on electronic health records. BMC Health Services Research, 20(1), 871. https://doi.org/10.1186/s12913-020-05688-3
Mackie, T. I., Cook, S., Crystal, S., Olfson, M., & Akincigil, A. (2020a). Antipsychotic Use Among Youth in Foster Care Enrolled in a Specialized Managed Care Organization Intervention. Journal of the American Academy of Child and Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2019.04.022
Mackie, T. I., Schaefer, A., Karpman, H. E., Lee, S. M., Bellonci, C., & Larson, J. (2020b). Systematic Review: System-wide Interventions to Monitor Pediatric Antipsychotic Prescribing and Promote Best Practice. Journal of the American Academy of Child and Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2020.08.441
Melvin, K. E., Hart, J. C., & Sorvig, R. D. (2017). Second-Generation Antipsychotic Prescribing Patterns for Pediatric Patients Enrolled in West Virginia Medicaid. Psychiatric Services, 68(10), 1061–1067. https://doi.org/10.1176/appi.ps.201600489
National Committee on Quality Assurance. (2021). Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET). Retrieved from https://www.ncqa.org/hedis/measures/initiation-and-engagement-of-alcohol-and-other-drug-abuse-or-dependence-treatment/
Neumann, P., Sanders, G. D., Russell, L. B., Siegel, J. E., & Ganiats, T. G. (2017). Cost-Effectiveness in Health and Medicine (2nd ed.). Oxford University Press.
Olfson, M., King, M., & Schoenbaum, M. (2015). Treatment of Young People With Antipsychotic Medications in the United States. JAMA Psychiatry, 72(9), 867–874. https://doi.org/10.1001/jamapsychiatry.2015.0500
Patel, N. C., Crismon, M. L., Hoagwood, K., Johnsrud, M. T., Rascati, K. L., Wilson, J. P., & Jensen, P. S. (2005). Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 44(6), 548–556. https://doi.org/10.1097/01.chi.0000157543.74509.c8
Penfold, R. B., Thompson, E. E., Hilt, R. J., Kelleher, K. J., Schwartz, N., Beck, A., . . . Simon, G. E. (2020). Safer use of antipsychotics in youth (SUAY) pragmatic trial protocol. Contemporary Clinical Trials, . doi:https://doi.org/10.1016/j.cct.2020.106184
Penfold, R. B., Thompson, E. E., Hilt, R. J., Schwartz, N., Robb, A. S., Correll, C. U., . . . Simon, G. E. (2021). Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer and Targeted Use of Antipsychotics (SUAY) Clinical Trial. J Am Acad Child Adolesc Psychiatry. doi:https://doi.org/10.1016/j.jaac.2021.04.010
Pennap, D., Burcu, M., Safer, D. J., & Zito, J. M. (2018). The Impact of a State Medicaid Peer-Review Authorization Program on Pediatric Use of Antipsychotic Medications. Psychiatric Services, 69(3), 293–299. https://doi.org/10.1176/appi.ps.201700177
Piovani, D., Clavenna, A., & Bonati, M. (2019). Prescription prevalence of psychotropic drugs in children and adolescents: An analysis of international data. European Journal of Clinical Pharmacology, 75(10), 1333–1346. https://doi.org/10.1007/s00228-019-02711-3
Saldana, L., Ritzwoller, D. P., Campbell, M., & Block, E. P. (2022). Using economic evaluations in implementation science to increase transparency in costs and outcomes for organizational decision-makers. Implement Sci Commun, 3(1), 40. https://doi.org/10.1186/s43058-022-00295-1
Salloum, R. G., Wagner, T. H., Midboe, A. M., Daniels, S. I., Quanbeck, A., & Chambers, D. A. (2022). The economics of adaptations to evidence-based practices. Implement Sci Commun, 3(1), 100. https://doi.org/10.1186/s43058-022-00345-8
U.S. Bureau of Labor Statistics. (2021). National Compensation Survey. Retrieved from https://www.bls.gov/ncs/data.htm
Yeung, K., Richards, J., Goemer, E., Lozano, P., Lapham, G., Williams, E., . . . Bradley, K. (2020). Costs of using evidence-based implementation strategies for behavioral health integration in a large primary care system. Health Services Research, 55(6), 913–923. doi:https://doi.org/10.1111/1475-6773.13592
Zito, J. M., Burcu, M., McKean, S., Warnock, R., & Kelman, J. (2018). Pediatric Use of Antipsychotic Medications Before and After Medicaid Peer Review Implementation. JAMA Psychiatry, 75(1), 100–103. https://doi.org/10.1001/jamapsychiatry.2017.3493
Funding
The project is supported by the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH) under contract number HHSN271201600002C, A Targeted Approach to a Safer Use of Antipsychotics in Youth (total award $9,658,552; no project costs were financed by nongovernmental sources). This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by NIMH or NIH.
Author information
Authors and Affiliations
Contributions
LC conducted the analyses and produced the first draft of the manuscript. All authors contributed to the design of the study, interpretation of the results, and reviewed and provided edits to the manuscript before submission.
Corresponding author
Ethics declarations
Competing Interests
The authors have no conflicts of interest to disclose that are relevant to this article. This publication was written prior to Dr. Kai Yeung joining Amazon.
Ethical Approval
The Institutional Review Board at each participating site reviewed and approved the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chavez, L.J., Richards, J.E., Fishman, P. et al. Cost of Implementing an Evidence-Based Intervention to Support Safer Use of Antipsychotics in Youth. Adm Policy Ment Health 50, 725–733 (2023). https://doi.org/10.1007/s10488-023-01273-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10488-023-01273-y